AMH ELISA Kit

evomedscience > Research > AMH ELISA Kit
Enzyme Immunoassay for the Quantitative Determination of AMH Concentration in Human Serum

Introduction

Anti-Mullerian Hormone (AMH) is a homodimeric glycoprotein linked by disulfide bonds. AMH is primarily produced by testicular tissue during early male embryonic development and plays a crucial role in the differentiation of male reproductive structures while inhibiting female reproductive organ development (Visser et al., 2012). In males, AMH levels are high in infancy and decrease gradually until reaching their lowest levels at puberty. In females, AMH is secreted by ovarian follicles and serves as a marker of ovarian reserve, as it reflects the number and quality of oocytes during folliculogenesis (La Marca & Volpe, 2006).

Unlike Follicle-Stimulating Hormone (FSH), Inhibin B, and Estradiol, AMH remains stable throughout the menstrual cycle, making it a reliable marker for ovarian reserve at any time (Broer et al., 2014). AMH levels are also independent of gonadotropin regulation and directly indicate the ovarian follicle pool. Clinically, AMH measurement is crucial in evaluating female fertility, especially in cases of Polycystic Ovary Syndrome (PCOS), premature ovarian insufficiency, and individuals undergoing chemotherapy or ovarian surgery (Dewailly et al., 2014). Elevated AMH levels are associated with an increased probability of success in assisted reproductive technologies (ART), including in vitro fertilization (IVF) (Iliodromiti et al., 2014).

Clinical Significance

AMH testing provides significant insights into reproductive health and endocrinology. It is widely utilized for:

  • Assessing ovarian reserve in fertility evaluations (Nelson et al., 2013).
  • Predicting response to ovarian stimulation in ART treatments (Broer et al., 2011).
  • Diagnosing PCOS, where elevated AMH levels reflect increased follicle numbers (Pigny et al., 2003).
  • Evaluating ovarian function after chemotherapy or ovarian surgery (Anderson & Cameron, 2011).
  • Predicting the onset of menopause (Tehrani et al., 2013).

Principle of the Assay

The AMH ELISA kit operates on a sandwich enzyme-linked immunosorbent assay (ELISA) principle. A monoclonal antibody immobilized on a microplate captures AMH from the test sample. After incubation and washing, a second monoclonal antibody conjugated with horseradish peroxidase (HRP) binds to the captured AMH, forming a sandwich complex. Following another incubation and wash step, a chromogenic substrate is added, leading to a colorimetric reaction proportional to AMH concentration. Absorbance is measured at 450 nm, allowing quantification against a standard curve.

References

  • Anderson, R. A., & Cameron, D. A. (2011). Pretreatment serum anti-mullerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. Journal of Clinical Endocrinology & Metabolism, 96(5), 1336-1343.
  • Broer, S. L., et al. (2011). AMH predicts ovarian response in IVF: A meta-analysis. Human Reproduction Update, 17(1), 46-54.
  • Dewailly, D., et al. (2014). The role of AMH in pathophysiology and diagnosis of PCOS. Human Reproduction Update, 20(3), 327-351.
  • La Marca, A., & Volpe, A. (2006). The anti-Mullerian hormone and ovarian reserve. Human Reproduction Update, 12(5), 555-571.
  • Visser, J. A., et al. (2012). Anti-Mullerian hormone: A new marker for ovarian function. Reproduction, 143(4), 519-530.